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Abstract 
For decades, antibiotics also called antimicrobial agents have been widely used in the treatment 
of infectious diseases. Nonetheless, the improper use of antibiotics has been reported in the 
literature globally as one of the primary causes of antibiotic /antimicrobial resistance 
(Laxminarayan et al., 2013). Indeed, the alarming magnitude of antibiotic/ antimicrobial 
resistance as a global public health threat deserves our full attention to implement evidence-
based interventions aiming at reducing this growing challenge (Tillotson, 2015). This paper will 
describe the issue of antibiotic/antimicrobial resistance in countries such as the United States, 
Canada, Europe, India, Pakistan, South Korea, Japan, South Africa, Brazil, Argentina and Haiti 
to provide an overview of the global burden of antibiotic/ antimicrobial resistance. The 
overarching goal of this paper is to explore the connections and gaps between the World Health 
Organization (WHO) strategic action plan on antibiotic/ antimicrobial resistance and the current 
policy in Haiti. Data was collected from sixteen key stakeholders including the Haitian Ministry 
of Health & Population (MSPP), the National Laboratory of Public Health (LNSP), the National 
Tuberculosis Program (PNLT), University teaching Hospitals and International organizations, 
selected for their ability to influence policy and/or decision making processes regarding 
antibiotic / antimicrobial resistance challenge in Haiti. Finally, the paper will conclude with the 
critical role of leadership in implementing the recommendations that aim to reduce the burden of 
antibiotic / antimicrobial resistance in Haiti. 
Keywords: antibiotic / antimicrobial resistance, global issue, World Health Organization 
(WHO) strategies, Haiti Ministry of Health (MSPP), policy recommendations.    
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Policy and practice recommendations for addressing antibiotic/antimicrobial resistance in Haiti 
The burden of antibiotic/antimicrobial resistance affects all nations on Earth, which jeopardizes 
the control of infection (Marinelli and Genilloud, 2013,2014)., The purpose of this Master paper 
is to provide a better understanding of antibiotic/antimicrobial resistance in Haiti. This paper will 
attempt to identify some similarities and gaps between the strategic action plan for addressing 
antimicrobial resistance suggested by the World Health Organization (WHO) and  data collected 
through  sixteen (16) semi-structured key informant interviews conducted in Haiti  The 
interviewees included organizations with strong partnerships with the Ministry of Health of Haiti 
such as the National Laboratory of Public Health (LNSP), the National Program of Fight against 
Tuberculosis (PNLT), University teaching Hospitals and some international organizations that 
have sufficient influence on policy and/or decision-making process. Finally, this paper will 
conclude with an emphasis on the value of leadership in the implementation of the reported 
practical recommendations in compliance to WHO guidelines, in order for Haiti to contribute to 
this global combat along with other countries. 
Definition of key terms 
 Pathogens include all living micro-organisms that have the capacity to quickly multiply and 
spread in hosts’ bodies (NIAID, 2009). These pathogens include bacteria like Mycobacterium 
Tuberculosis, which causes Tuberculosis; viruses like Hemophilus Influenza, which causes Flu; 
fungi like Candida Albicans, which causes Yeast infections; and parasites like Plasmodium 
Falciparum, which causes Malaria. Antibiotic/ antimicrobial agents can be defined as medical 
drugs used to treat infections, which prevent harm from pathogens by either limiting their growth 
or by killing them (WHO, 2011). Antibiotic/antimicrobial resistance (AMR) occurs when a set of 
mutations in the gene of a pathogen makes it resistant to the antimicrobial drug originally 
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effective to treat the infection (Lopez-Lozano et al., 2000). Finally, Hospital Acquired Infection 
(HAI) happens when pathogens are unintentionally spread across patients and providers in 
healthcare settings (Deshpande et al., 2007). 
Literature review 
 
A wide range of studies reported that methicillin-resistant Staphylococcus aureus (MRSA) and/ 
or multidrug-resistant Gram-negative bacteria are accountable for the majority of antibiotic/ 
antimicrobial resistance and hospital-acquired infections globally (David and Daum, 2010). In 
2015 multi-drug resistant Tuberculosis (MDR-TB) and extensively drug-resistant Tuberculosis 
(XDR-TB) led to an estimated 190,000 deaths worldwide (Frieden, 2016).  This review 
illustrates the burden of the global of antibiotic/ antimicrobial resistance by presenting examples 
from a few select countries and regions around the world. This is not a systematic review, but is 
intended to demonstrate that the problem of antimicrobial resistance is truly a worldwide 
phenomenon. 
United States  
 
In the United States, an estimated of 23,000 deaths result from antibiotic/ antimicrobial 
resistance especially in healthcare settings nationwide every year (CDC, 2013). Overall, the most 
prevalent resistant pathogens reported in the literature across several studies, were: methicillin-
resistant staphylococcus aureus (MRSA), multidrug-resistant Escherichia Coli (MDR- E. Coli) 
and Carbapenem-resistant Enterobacteriaceae (Singh et al., 2015; Sievert et al., 2013; Multari et 
al., 2013; Hidron et al., 2008; Dan et al., 2016; Ibekwe et al., 2016; Stephen and Jones, 2002). 
Studies reported that 76% of all Hospital Acquired Infections (HAIs) were found to be 
methicillin-resistant staphylococcus aureus (MRSA) and that 89% were vancomycin-resistant 
(Singh et al., 2015).  Pseudomonas aeruginosa, another leading cause of Hospital Acquired 
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Infections (HAIs) has developed resistance to almost all antibiotics (CDC, 2014). Clostridium 
difficile has also become resistant to standard antibiotics in health care settings (Munro, 2015). 
Moreover, a report in 2014 mentioned the financial burden of antimicrobial resistance on the 
health systems showing that it cost the US $ 150,000 per case of multidrug resistance 
Tuberculosis (MDR-TB) and $ 482,000 per case of extensively drug resistance Tuberculosis 
(XDR-TB) (CDC, 2015). 
Canada 
A study conducted across several Canadian Hospitals reported that methicillin-resistant 
staphylococcus aureus (MRSA) was accountable for 68.8% of antimicrobial resistance in 
hospital settings compared to 27.6% in community settings (Zhanel et al., 2010). Also, every 
year the pathogen Neisseria gonorrhoeae infects an estimated 13,000 individuals and it found to 
be resistant to standard antibiotics (Martin et al., 2016).   
Europe  
 
Methicillin-resistant staphylococcus aureus (MRSA) has been reported by the European Society 
of Clinical Microbiology and Infectious Diseases as an alarming public health threat due to its 
exponential trend (Rossolini and Mantengoli, 2008). Also, in 2013 Estonia, Latvia and Romania 
in Central Europe represented the leading countries carrying the burden of multidrug resistance 
Tuberculosis (MDR-TB) (Stagg et al., 2015). A study conducted in Barcelona reported that 
resistant strains of Escherichia Coli (E. Coli) were highly prevalent in neonatal sepsis (Guiral et 
al., 2012). 
India 
A study conducted across several Pediatric centers in Chennai reported a prevalence of 4% of 
multidrug resistance Tuberculosis (MDR-TB) in children (Swaminathan, 2012). 
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Pakistan 
Pakistan Among the 27 countries highly prevalent with multidrug resistance Tuberculosis 
(MDR-TB), Pakistan holds the 5th position (WHO, 2014). In 2013 Pakistan managed to link only 
13% (1,570/12,997) of the diagnosed cases of MDR-TB to appropriate medical care, (Safdar, 
2014).  
South Korea 
A study conducted from 2005 to 2014 nationwide reported that 41.2% (28/68) of the Salmonella 
Virchow pathogens were found to be cefotaxime-resistant (Jin Seok et al., 2016). Another 
research study assessed the antimicrobial susceptibility of Escherichia Coli (E. Coli) from cattle 
farms across the country and reported a high prevalence of resistance to first line antibiotics like 
Streptomycin (63.1%) and Tetracycline (54.5%) (Shin et al., 2014).  
Japan  
A nationwide survey conducted across 27 Medical centers in 2010 reported a very high 
prevalence (72%) of methicillin-resistant Staphylococcus aureus (MRSA) among 586 
hospitalized patients (Takesue et al., 2012).  
South Africa 
A study from Johannesburg supported the evidence of a high prevalence (8.8%) of multidrug 
resistance Tuberculosis (MDR-TB) (Fairlie et al., 2011). Similarly, reports from Cape Town 
argued an increasing trend (2.3 to 6.7%) for the prevalence of MDR-TB in childhood (Schaaf et 
al., 2009).  
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Brazil 
An exploration of the Brazilian Amazon reported a prevalence of 5.2% (7/135) of the patients 
infected with Plasmodium Vivax being resistant to the standard treatment with Chloroquine, 
which hinders the control of Malaria (Marques et al., 2014).  
Argentina 
A study conducted across several Argentinean medical centers argued a growing prevalence of  
pathogens resistant to the class of antibiotics called Carbapenem (Tognim et al., 2004).   
Haiti  
 
Although in Haiti there is no national data on antibiotic/ antimicrobial resistance overall, some 
published data are available regarding multidrug resistance Tuberculosis (MDR-TB). In 2000 the 
“Groupe Haıtien d’Etude du Sarcome de Kaposi et des Infections Opportunists (GHESKIO)” 
Research Center conducted a 2-year study across a few HIV/AIDS management sites involving 
330 patients to report a prevalence of 20% (10/49) of MDR-TB from recurrent TB cases (Joseph 
et al., 2006).  Another study from GHESKIO reported a prevalence of 2.9% of MDR-TB among 
906 patients diagnosed with TB for the first time (Ocheretina et al., 2012).  
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Summary of the literature review 
Table 1 
Summary of the data from this informal review of the literature, showing the pathogens that are 
most prevalent in the various countries. 
Country Reported resistant-pathogens Data sources 
United States 
Methicillin-resistant staphylococcus aureus (MRSA) 
Multidrug-resistant Escherichia Coli (MDR- E. Coli)  
Carbapenem-resistant Enterobacteriaceae 
Pseudomonas aeruginosa 
Clostridium difficile 
Singh et al., 2015 
Sievert et al., 2013 
Multari et al., 2013 
Hidron et al., 2008 
Dan et al., 2016 
Ibekwe et al., 2016 
Stephen and Jones, 2002  
CDC, 2014 
Munro, 2015 
Canada 
Methicillin-resistant staphylococcus aureus (MRSA) 
Neisseria gonorrhoeae 
Zhanel et al., 2010 
Martin et al., 2016 
Europe  Methicillin-resistant staphylococcus aureus (MRSA) 
Multidrug resistance Tuberculosis (MDR-TB) 
Multidrug-resistant Escherichia Coli (MDR- E. Coli)  
Rossolini and Mantengoli, 2008 
Stagg et al., 2015 
Guiral et al., 2012 
India Multidrug resistance Tuberculosis (MDR-TB) Swaminathan, 2012 
Pakistan Multidrug resistance Tuberculosis (MDR-TB)  
WHO, 2014 
Safdar, 2014 
South Korea 
Salmonella Virchow pathogens 
Multidrug-resistant Escherichia Coli (MDR- E. Coli)  
Jin Seok et al., 2016 
Shin et al., 2014 
Japan Methicillin-resistant staphylococcus aureus (MRSA) Takesue et al., 2012 
South Africa Multidrug resistance Tuberculosis (MDR-TB) 
Fairlie et al., 2011 
Schaaf et al., 2009 
Brazil Plasmodium Vivax Marques et al., 2014 
Argentina Carbapenem-resistant Enterobacteriaceae Tognim et al., 2004 
Haiti  Multidrug resistance Tuberculosis (MDR-TB) 
Joseph et al., 2006 
Ocheretina et al., 2012 
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 In conclusion, the following points are noteworthy:  
 Antibiotic/antimicrobial resistance represents a serious public health issue 
worldwide 
 The pool of pathogens resistant to first line antibiotics displays strong similarities 
globally, although there might be some regional differences 
Based on these evidence, even though Haiti does not have a strong health system to assess the 
magnitude of antibiotic/antimicrobial resistance and collect data to drive and implement an 
action plan, it is reasonable to conclude that Haiti will more likely display similar patterns of 
resistance. Available data on MDR-TB in Haiti support this argument.  
WHO strategies to address the global issue of antibiotic/antimicrobial resistance 
As a global public health issue, addressing antibiotic/antimicrobial resistance requires a global 
response. Therefore, the WHO calls for concerted global attack against antibiotic/antimicrobial 
resistance, which requires strong leadership, ongoing advocacy and sufficient resources (WHO, 
2011). A global action plan proposed by the WHO identified the following five key strategies to 
address antimicrobial resistance (WHO, 2015):  
1. Improve awareness and understanding of antibiotic/ antimicrobial resistance through 
effective communication, education and training 
This strategy aims at encouraging nations to react against antimicrobial resistance 
through promotion and advocacy for antibiotics stewardship and behavioral 
change.  
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2. Strengthen the knowledge and evidence-based through research and surveillance 
This strategy emphasizes the urgency to reinforce the capacity of laboratories in 
identifying bacteria and assessing their susceptibility to antimicrobial drugs with 
the ultimate goal of implementing or strengthening laboratories-based 
surveillance systems. Systems that would proactively report cases of antimicrobial 
resistance for further actions. 
3. Reduce the incidence of infection through effective hygiene and infection prevention 
measures 
This strategy aims at promoting best practices of hygiene, use of vaccines as well 
as evidence-based infections control in healthcare settings. 
4. Optimize the use of antimicrobial medicines in human and animal health 
This strategy encourages the control of access to medicines through partnerships 
across stakeholders involved in authorization, production, distribution, control 
and use of veterinary antimicrobial agents, as well as the publication of the lists of 
essential medicines as guidelines for providers.  
5. Develop the business case for sustainable investment that considers the needs of all 
countries, as well as the need for investment in new medicines, diagnostic tools, vaccines 
and other interventions 
This strategy aims at finding cost-effective approaches to engage and incentivize 
health researchers to develop new medical drugs with the potential of treating 
current resistant infections.  
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To understand the extent to which these five strategies are currently applied in Haiti to address 
antibiotic/ antimicrobial resistance, a set of semi-structured interviews was conducted with key 
stakeholders in leadership positions including the ministry of Health (MSPP) about their insights. 
In December 2015. Institutional Review Board (IRB) approval was obtained from both the 
University of North Carolina (UNC) at Chapel Hill and the National Bioethics Committee of 
Haiti.  
Summary of interviews’ results 
For confidentiality reasons, the data collected will remain anonymous as agreed with the 
interviewees. Instead of individual quotes, the responses from all the non-governmental 
interviewees will be aggregated and compared to the Ministry of Health’s (MSPP) perspective 
for each of the five strategies proposed by WHO.  
 
WHO strategy # 1: Improve awareness and understanding of antibiotic/ antimicrobial 
resistance through effective communication, education and training (Please refer to page 9). 
Ministry of Health (MSPP) perspective 
Issues Identified What has been done What needs to be done 
 No assessment of antibiotic / 
antimicrobial resistance. 
 
 Several campaigns have been 
launched against antibiotic/ 
antimicrobial resistance. 
 
 Regulation of the use and selling 
of medical drugs at least in Port-
Au-Prince. 
 Expansion of the regulation of 
medical drugs nationwide. 
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Key Stakeholders perspective 
Issues Identified What has been done What needs to be done 
 Unavailability of data to 
confirm if antibiotic/ 
antimicrobial resistance is a 
public health issue. 
 
 Lack of motivation of the 
parliament to pass a policy even 
to make mandatory MDR-TB 
treatment. 
 
 Antibiotic/ antimicrobial 
resistance might be a public 
health problem because of the 
current misuse of antibiotics in 
Haiti. 
 
 Not enough trained public 
health professionals working at 
the Ministry of Health (MSPP) 
able to help identifying key 
priorities and strengthen our 
Health systems. 
 Availability of data for MDR-TB 
 
 
 
 
 
 
  
 Provide national guidelines for 
healthcare providers to follow to 
foster a better standardization of 
care delivery. 
 
 Train providers on antibiotics use. 
 
 
 Use the partnerships of the 
Ministry to provide scholarships 
to potential candidates interested 
in public health and willing to 
serve Haiti. 
 
 
 
 
 
 
 
 
WHO strategy # 2: Strengthen the knowledge and evidence-based through research and 
surveillance (Please refer to pages 9-10 for details). 
Ministry of Health (MSPP) perspective 
Issues Identified What has been done What needs to be done 
 Availability of specific data 
about antibiotic/ antimicrobial 
resistance in Haiti requires 
capacity building of institutions 
to systematically investigate the 
patterns of resistance, which is 
currently not widely available 
in Haiti. 
 
 
 
 Pharmaceutical agencies are 
required to receive authorization 
from this Ministry every time they 
are ordering medicines from 
abroad in order to track the 
laboratory producing the 
medicines imported by Haiti for 
quality assurance. 
 
 Partnerships for pharmaco-
vigilance with countries like 
Belgium, USA (FDA) to 
exchange data on the quality of 
the medicines on the market to 
protect the nation.  
 
 Reinforcement of the policy to 
regulate the entry of medicines 
in Haiti, because not all the 
drugstores are registered with 
this Ministry.  
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Key Stakeholders perspective 
Issues Identified What has been done What needs to be done 
 Lack of microbiology 
laboratories. 
 
 Lack of infectious diseases 
specialists. 
 
 Very limited access to 
microbial cultures and 
resistance tests. 
 
 30% of 3,000 patients who 
received Highly Active 
Antiretroviral Therapy 
(HAART) failed to reach an 
undetectable Viral load. 
 
 Two research projects 
addressing antibiotic/ 
antimicrobial resistance in at 
risk population for Cholera, 
MDR-TB using GeneXpert 
and culture of germs via 
Drugs sensitivity tests (DST). 
 
 Only three organizations in 
the public sector have the 
capacity to do microbial 
resistance tests. 
 
 Currently a pilot research 
study on HIV resistance aims 
to collect data on HIV 
genotyping to assess if there 
would be an association 
between the reported 
therapeutic failure cases and 
HAART-resistant HIV. 
 
 Provide the Departmental hospitals 
adequate laboratories with the 
capacity to do cultures to document 
antibiotic/ antimicrobial resistance 
nationwide. 
 
 Improve access to affordable 
laboratory tests. 
 
 
 
 
 
WHO strategy # 3: Reduce the incidence of infection through effective hygiene and infection 
prevention measures (Please refer to page 10 for details). 
Ministry of Health (MSPP) perspective 
Issues Identified What has been done What needs to be done 
 People who live in urban areas 
are likely to be exposed to 
healthcare settings and at risk 
for resistant nosocomial 
infections. 
 
 Practice of self-medication 
with antibiotics. 
 
 
 Reinforce education on 
hygiene nationwide through 
campaigns to raise public 
awareness as done in response 
to the Cholera epidemic 
 
 Educate more the population. 
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Key Stakeholders perspective 
Issues Identified What has been done What needs to be done 
 No policy or law to isolate or 
put in quarantine people 
diagnosed with MDR-TB. 
 
 Lack of asepsis in healthcare 
settings 
 Nothing reported 
 
 Train more healthcare professionals 
especially the University students in 
infectious diseases and microbiology 
to promote the control of infections. 
 
 Availability of running water in all 
healthcare facilities to foster hand-
washing and reduce the spread of 
resistant nosocomial pathogens. 
 
WHO strategy # 4: Optimize the use of antimicrobial medicines in human and animal health 
(Please refer to page 10 for details). 
Ministry of Health (MSPP) perspective 
Issues Identified What has been done What needs to be done 
 No policy in place yet to 
specifically mitigate the 
occurrence of antibiotic/ 
antimicrobial resistance. 
 
 Consumption of imported 
poultry from countries where 
antibiotics is heavily used in 
livestock. 
 
 The biggest challenge to 
destroy expired stock of 
medicines. 
 
 Lack of resources available 
for this Ministry to 
implement sustainable 
interventions against the 
current practices. 
 
 Within this Ministry, the 
direction of care oversees the 
prescription of antibiotics for 
clinical sites. 
 
 Regulations of the registered 
drugstores have been reinforced 
by requiring them to hire at least 
one pharmacist to manage and 
control their expired medicines. 
 
 Shortening of the license renewal 
period of registered drugstores 
from 2-3 years to 1 year now. 
 
 Involvement of the Association 
of private hospitals in this 
pharmaco-vigilance, where 
copies of all the prescriptions are 
available and saved to report to 
this Ministry for review to see if 
there was an order for lab 
tests/culture associated with the 
prescribed antibiotics. 
 Availability of incentives to 
motivate owners of medical drugs 
to destroy their expired stock.  
 
 Establish a surveillance system for 
emergent antibiotic/antimicrobial 
resistance. 
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Key Stakeholders perspective 
Issues Identified What has been done What needs to be done 
 No existing policy in place to 
control the entry of donated 
medicines and assess their quality. 
 
 No national document available 
addressing 
antibiotic/antimicrobial resistance. 
 
 Set of risk factors for antibiotic/ 
antimicrobial resistance in Haiti: 
self-medication, selling of 
medicines in the streets exposed 
to the sunlight, rain, humidity, 
misconception of the effects of 
antibiotics by the general public, 
adoption of a syndromic approach 
by healthcare providers in 
response to limited access to 
laboratory tests. 
 
 The well-known practice where 
many women buy and consume 
antibiotics without prescription 
after their periods to clean up and 
prevent infections (personal 
beliefs).  
 
 Nothing reported. 
 
 Training and coaching on 
antibiotics stewardship for 
prescribers and dispensers of 
antibiotics nationwide. 
 
 Educate the general population on 
the appropriate use of antibiotics 
and the consequences of their 
misuse considering the socio-
economic and cultural components 
as barriers. 
 
 Some classes of antibiotics should be 
allowed to be prescribed only by 
infectious disease specialists.  
 
 
 Use legal means to ban the selling 
of medicines including antibiotics 
in the streets.  
 
 
 
WHO strategy # 5:  Develop the business case for sustainable investment that considers the 
needs of all countries, as well as the need for investment in new medicines, diagnostic tools, 
vaccines and other interventions (Please refer to page 10 for details). 
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Ministry of Health (MSPP) perspective 
Issues Identified What has been done What needs to be done 
 No specific issue reported. 
 
 
 Progressive removal of the 
streets vendors of medicines 
from the market using a trade-off 
approach, where they received 
stocks of iodine salt to sell in the 
streets instead of the medicines 
that they used to buy. 
 Eliminate the streets vendors of 
medicines by promoting 
agriculture and the exportation of 
their food to ensure sufficient 
income for their living expenses 
while protecting the population. 
 
 Support from potential 
international partners to foster 
better access to new protocols of 
antibiotics. Financial assistance to 
buy these new antibiotics required 
to handle antimicrobial resistance, 
in order to subsidize the vulnerable 
people in need, because otherwise 
they will more likely die from their 
resistant infections despite the 
advances of health research.  
 
Key Stakeholders perspective 
Issues Identified What has been done What needs to be done 
 Nothing reported  Nothing reported  Nothing reported 
 
 
WHO perspectives on Haiti’s Health System capabilities to address antimicrobial resistance 
WHO argued that it is critical to prevent infections from occurring in the first place as a cost-
effective approach to reduce the need for antibiotics by doing the following: “Better hygiene, 
Access to clean water and sanitation, Infection control in healthcare facilities, Vaccination” 
(WHO, 2014). However, the Haitian health systems makes it difficult to implement these 
activities. The lack of infrastructure of the Haitian Ministry of Health has led to the fact that 
almost 80% of the population rely on traditional medicine as their first resource for healthcare 
due to several reasons such as access to care, cost, personal beliefs (PAHO/WHO, 2012). Indeed, 
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the sad reality on the ground is that except for HIV/AIDS, TB, and Malaria there are no national 
standard treatment guidelines and antibiotics are frequently sold over the counter without a 
prescription which hinders the rational use of pharmaceuticals (PAHO/WHO, 2012). Moreover, 
the Haitian Government does not have a national policy that sets the price of medical drugs and 
regulates their prescriptions and selling except for narcotic medical drugs (MSPP, 2014). Fewer 
than five pharmaceutical laboratories are officially designated to produce drugs for national use 
and “supply approximately 30% to 40% of the Haitian market”, but there is a quasi-absence of 
official guidelines or regulations for donated medicines which may foster the use of expired 
medicines by the population (PAHO/WHO, 2012).  
Discussion 
Based on the results of the interviews, it appears that major gaps exist in the implementation of 
all WHO strategies in Haiti. Both the Ministry of Health (MSPP) and the key stakeholders 
acknowledged that the quasi-absence of assessment of antibiotic/ antimicrobial resistance, made 
it hard to objectively support that it would be a public health issue in Haiti, despite the current 
unregulated conditions of antibiotics use nationwide. However, the stakeholders identified the 
following major issues:  
 Limited access to microbiology laboratories. 
 Misuse of antibiotics, absence of policy to regulate the selling of medical drugs 
except for the narcotic drugs. 
 Misperceptions of antibiotics use by the population. 
 Absence of surveillance systems to document cases of antibiotic/ antimicrobial 
resistance.  
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 The Ministry of Health felt that policies were in place to regulate the selling of medical drugs, 
but this was not perceived by other stakeholders. However, there was general agreement that 
there is need for educating the general public and healthcare providers on the dangers of 
antimicrobial resistance. It is also clear that a significant amount of research is needed to 
understand the extent of antimicrobial resistance in Haiti. Instead of having the few research 
organizations work in silo to conduct studies on MDR-TB with a sample size of subjects that is 
not necessarily representative of the population, it would be more beneficial to work 
collaboratively. By doing so, Haiti would be able to collect and report reliable data on antibiotic/ 
antimicrobial resistance from all the well-equipped public and private laboratories that would 
convene to launch and lead a National assessment of antibiotic/ antimicrobial resistance under 
the Ministry of Health (MSPP) oversight. Furthermore, the MSPP should expand the practice of 
peer audit of prescriptions to bring about changes in prescribing behavior across providers in 
both public and private sectors.  Finally, Haiti’s Health system needs to be substantially 
strengthened and capacity should be built in the areas of assessment, awareness, surveillance and 
vigilance, antibiotics stewardship, training, policy enforcement, and sustainable investment. 
Recommendations 
In summary, the following policy and practice recommendations can be made to further 
understand and address Haiti’s antimicrobial drug resistance problem:  
 Educate the general public and the providers on antibiotics stewardship 
 Develop and apply policy to regulate and control the selling, consumption and 
destruction of all medical drugs, not just for the narcotic drugs like morphine 
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 Request assistance from the International community and partners to strengthen the 
capacity of at least the Universities and Departmental laboratories to improve access 
to labs tests 
 Integrate a section for antibiotic/antimicrobial resistance into the current surveillance 
systems that reports to the Ministry of Health data on Cholera, HIV/AIDS, 
Tuberculosis 
 Elaborate national guidelines to standardize the quality of care, in addition to those 
for Tuberculosis, HIV/AIDS, Cholera, Malaria 
 Communicate and disseminate the progress and challenges of this Ministry, to engage 
more stakeholders and experts in this critical initiative 
 
Role of leadership 
Clearly leadership plays a very important role in addressing antibiotic/ antimicrobial resistance. 
As reported by the key stakeholders, the strategies implemented by the Ministry of Health 
(MSPP) are unknown by the practitioners, health facilities leaders and possibly by the general 
public. Therefore, the leadership team of this Ministry needs to become more assertive to 
articulate not only the needs but also the progress and barriers of its initiatives and to involve a 
broader set of stakeholders in assessment and in the design and implementation of interventions. 
This Ministry should also seek strong commitment from the legal system like the Ministry of 
Justice and the Parliament to enforce the law in support of antibiotics stewardship as well as to 
implement prospective policy that would allow providers to initiate mandatory treatment and 
isolation of all diagnosed MDR-TB people for the safety of the entire population. 
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Conclusion 
To date antibiotic/ antimicrobial resistance remains an alarming public health issue globally. And 
the literature has not yet reported a single country that has fully tackled all the components of 
this major challenge. As with all health issues, better resourced countries like the United States 
seem to be more successful in addressing for example MDR-TB compared to others like Pakistan 
and Haiti.  The World Health Organization (WHO) has developed an action plan as guidelines to 
mitigate the situation. As this paper shows, Haiti has taken some steps to follow these guidelines, 
but much still needs to be done, as confirmed by both reports in the literature and the opinion of 
the interviewed stakeholders.  The Ministry of Health must be encouraged to take on a strong 
leadership role to address the policy and practice recommendations outlined in this paper. 
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Appendix  
Interview questionnaires 
A1) English version of the questionnaire interview for the Ministry of Health Officials of 
Haiti (MSPP) 
Disclosure: Thank you for taking the time to meet with me and please note that the information 
that you will share with me here will be included in my Master Paper which is about “Policy and 
practice recommendations for addressing Antimicrobial Resistance in Haiti: using the 
Public Health Quality Aims”  
 
Interviewer/PI: Marie Lina Excellent (MPH student in PHLP at UNC – Chapel Hill, NC and 
Fulbright Scholar from Haiti) 
Name of interviewee:  
Organization:  
Role /job position: 
For how long have you held this position? 
 
Set of questions for Officials from the Ministry of Health of Haiti, such as: 
Minister of Health or Current General Director of the Ministry of Health 
Former General Director of the Ministry of Health 
Three categories of questions: 
A) I would like to understand the current state of antimicrobial resistance in Haiti  
 Would you consider antimicrobial resistance be a public health issue in 
Haiti?  
 Would you like to share any relevant information that we should know 
about the current status of antimicrobial resistance in Haiti? 
 How would you describe the impact of antimicrobial resistance in Haiti? 
 Would there be a difference between people living in rural versus urban 
areas in terms of being at risk for that issue? 
ANTIMICROBIAL RESISTANCE GLOBAL ISSUE                                                            27 
 
 Does the Ministry of Health have a system in place to collect data or 
reports from hospitals and organizations partners about antimicrobial 
resistance?  
 Based on your perspective what would be the top conditions that have led 
to antimicrobial resistance in Haiti?  
 
B) I would like to learn about the current policy in place in Haiti regarding 
Antimicrobial Resistance  
 Does the Ministry of Health consider antimicrobial resistance a public health 
priority?  
 Does the Ministry of Health have an existing policy addressing antimicrobial 
resistance in Haiti? If yes, how was it implemented nationwide?  
 Does the Ministry of Health have a strategic plan to address antimicrobial 
resistance in Haiti? If yes, how was the piloting phase? How was it received 
by the general public and key stakeholders like healthcare providers, 
pharmaceutical agencies? What were some identified barriers to 
implementation? 
 Is there a surveillance system established by the Ministry of Health to collect 
and monitor data about antimicrobial resistance? 
 Does the Ministry of Health use the resources from the National Lab of Public 
Health to investigate the threat of antimicrobial resistance in Haiti? 
 On September 2014 the Ministry of Health of Haiti published the National 
Pharmaceutical policy in which it is clearly stated that there are insufficient 
regulations and legislation to control the selling of medicines at national 
level? How would you address that?  
 Do you have written legislations or process to enforce compliance to 
regulations regarding prescriptions, selling of antibiotics at National level? 
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C) I would like to hear about your willingness to accept and implement 
recommendations 
 What type of support would be the most helpful to the Ministry of Health in 
developing and implementing policy related to antimicrobial resistance?  
 What would be some recommendations for addressing antimicrobial 
resistance in Haiti? 
 Please complete this sentence: As an official of the Ministry of Health, if I 
was asked by the Ministry of Health to provide one strategy or idea to address 
antimicrobial resistance in Haiti, I would say ………. 
 Has public health quality ever been considered when framing strategies for 
Antimicrobial Resistance in Haiti? Would Haiti be open to consider using an 
HHS framework for public health quality (Population-centered, Vigilant, 
Transparent, Efficient, Risk reducing, Effective, Health promoting, Proactive 
and Equitable) for developing a set of population-based strategies? 
 What kind of support is the needed for (a) the development of policy to 
address antimicrobial resistance and (b) the implementation of the policy? 
Among the partners of the Ministry of Health do you in mind who might be 
able to provide that kind of support?  
 Please feel free to provide any recommendations to improve this threat in 
Haiti 
 
Any final words: 
Thank you very much! 
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A2) English version of the questionnaire interview for key stakeholders/partners of Haiti 
Ministry of Health (MSPP) 
Disclosure: Thank you for taking the time to meet with me and please note that the information 
that you will share with me here will be included in my Master Paper which is about “Policy and 
practice recommendations for addressing Antimicrobial Resistance in Haiti: using the 
Public Health Quality Aims”  
 
Interviewer/PI: Marie Lina Excellent (MPH student in PHLP at UNC – Chapel Hill, NC and 
Fulbright Scholar from Haiti).   
Name of interviewee:  
Organization:  
Role /job position: 
For how long have you held this position? 
Three categories of questions: 
A) I would like to understand the current state of antimicrobial resistance in Haiti  
 Would you consider antimicrobial resistance be a public health issue in 
Haiti?  
 Is your organization involved in any surveillance for antimicrobial 
resistance?  
 Would you like to share any relevant information that we should know 
about the current status of antimicrobial resistance in Haiti? For example, 
in your hospital have you ever come across cases of antimicrobial 
resistance? If yes, how were the case managed?  
 How would you describe the impact of antimicrobial resistance in Haiti? 
Would there be a difference between people living in rural versus urban 
areas in terms of being at risk for that issue? 
 Based on your perspective what would be the top conditions that have led 
to antimicrobial resistance in Haiti?  
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B) I would like to learn about any existing policy in place in Haiti regarding 
Antimicrobial Resistance  
 Is antimicrobial resistance a priority for your organization?  
 Do you implement in your organization any policy to address antimicrobial 
resistance?  
 Is there an established procedure in your organization to collect data related to 
antimicrobial resistance and then report them to the Ministry of Health for 
follow up?  
 On September 2014 the Ministry of Health of Haiti published the National 
Pharmaceutical policy in which it is clearly stated that there are insufficient 
regulations and legislation to control the selling of medicines at national level. 
Would you like to share any thoughts about it?  
 Based on your perspective what the Ministry of Health should include in a 
strategic plan to address antimicrobial resistance in Haiti? And what would 
you anticipate as being the major barriers to the effective implementation of a 
policy?  
 Do you have any plan to implement strategies against antimicrobial 
resistance?  
 What are some recommendations for addressing antimicrobial resistance in 
Haiti? 
 For Pharmaceutical agencies ONLY: Do you have a process in place to 
mitigate antimicrobial resistance? Do you have specific procedures on selling 
medicines to independent individuals, pharmacists, etc? 
 For Hospitals Seniors ONLY: Do you know if your hospital acknowledges 
the threat of antimicrobial resistance and what have been done about it? If yes, 
what is the approach? For example, do you implement educational messages 
about it to be shared at different levels like in the waiting room with the 
patients, small handouts or flyers in the outpatient clinics for providers, case 
studies about during academic activities with the residents and interns?  
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 For National Lab of Public Health ONLY: Does the National lab currently 
work on projects that address antimicrobial resistance in Haiti? If yes, how do 
you track antimicrobial resistance? 
C) I would like to hear about your willingness to accept and implement 
recommendations 
 Based on your perspective what type of support would be the most helpful to 
the Ministry of Health in developing and implementing policy related to 
antimicrobial resistance?  
 Would your organization be willing to consider recommendations from my 
policy brief which will be sent out to a scientific journal with an attempt for 
publication regarding antimicrobial resistance in the context of Haiti? 
 Have you heard of the public health quality aims?  Would your organization 
be open to consider using an HHS framework for public health quality 
(Population-centered, Vigilant, Transparent, Efficient, Risk reducing, 
Effective, Health promoting, Proactive and Equitable) to assist the Ministry of 
Health in developing a set of population-based strategies? 
 Please feel free to provide any recommendations to improve antimicrobial 
resistance threat in Haiti 
 Please complete this sentence: If my organization was asked by the Ministry 
of Health to provide one strategy or idea to address antimicrobial resistance in 
Haiti, I would say ………. 
 
Any final words:  
Thank you very much! 
 
 
 
 
 
